Journal of Molecular Structure, cilt.1208, 2020 (SCI-Expanded)
Chalcones and their derivatives are increasing attention due to numerous biochemical and pharmacological applications. In this study, a series of novel organohalogen chalcone derivatives (5-12) were tested towards alpha-glycosidase (alpha-Gly), acetylcholinesterase (AChE) human carbonic anhydrase I (hCA I), and carbonic anhydrase II (hCA II) enzymes. These compounds (5-12) showed K,s in ranging of 16.24 - 40.96 nM on hCA I, 29.61-67.15 nM on hCA II, 1.21-4.39 nM on AChE and 12.54-35.22 nM on alpha-glycosidase. The novel organohalogen chalcone derivatives (5-12) had effective inhibition profiles against all tested metabolic enzymes. Also, because of the enzyme inhibitory effects of the compounds (5-12), they have the potential of drug candidates to treat of some diseases including epilepsy, glaucoma, type-2 diabetes mellitus (T2DM), Alzheimer's disease (AD), and leukemia. Also, the chalcone derivatives with best inhibition score docked into the active site of indicated metabolic enzymes receptors. Bro-mobenzyle and chlorophenyl moieties of chalcone derivatives contribute to their inhibitor properties on the enzymes. (C) 2020 Published by Elsevier B.V.